Abstract
Background: Atazanavir, an azadipeptide protease inhibitor (PI) with once daily dosing, a lack of insulin resistance, lipid increase, and gastrointestinal toxicities, is approved in combination with other antiretrovirals for the...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have